PHLPP-1 negatively regulates Akt activity and survival in the heart

Shigeki Miyamoto1, Nicole H Purcell, Jeffrey M Smith

  • 1Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093-0636, USA. smiyamoto@ucsd.edu

Circulation Research
|June 26, 2010
PubMed

Insights

PHLPP-1 (PH domain leucine-rich repeat protein phosphatase-1) inhibits Akt signaling in heart cells. Blocking PHLPP-1 enhances Akt activity and provides significant cardioprotection against injury.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cell Signaling

Background:

  • PH domain leucine-rich repeat protein phosphatase-1 (PHLPP-1) dephosphorylates Akt at Ser473, inhibiting Akt signaling in cancer cells.
  • The role of PHLPP-1 in cardiac physiology and cardioprotection remains uninvestigated.

Purpose of the Study:

  • To investigate the role of PHLPP-1 in the heart.
  • To determine if inhibiting PHLPP-1 enhances Akt signaling and provides cardioprotection.

Main Methods:

  • PHLPP-1 knockdown using small interfering RNA in neonatal rat ventricular myocytes (NRVMs) and adult mouse ventricular myocytes (AMVMs).
  • Generation and analysis of PHLPP-1 knockout (KO) mice.
  • Assessment of Akt phosphorylation (p-Akt) at Ser473 and Thr308, Akt catalytic activity, and mitochondrial Akt signaling.
  • Evaluation of cardioprotection against doxorubicin and H2O2-induced injury in vitro.
  • Assessment of infarct size in isolated perfused hearts subjected to ischemia/reperfusion.

Main Results:

  • PHLPP-1 knockdown in NRVMs and AMVMs potentiated Akt phosphorylation at Ser473 and increased Akt catalytic activity.
  • PHLPP-1 knockdown conferred cardioprotection against doxorubicin and H2O2.
  • PHLPP-1 localizes to mitochondria, and its knockdown enhanced mitochondrial Akt signaling and hexokinase-II levels.
  • PHLPP-1 KO mice exhibited potentiated Akt signaling in response to agonists and during ischemia/reperfusion.
  • PHLPP-1 KO hearts showed reduced infarct size following ischemia/reperfusion.

Conclusions:

  • PHLPP-1 acts as an endogenous negative regulator of Akt activity and cell survival in the heart.
  • Inhibition of PHLPP-1 represents a potential therapeutic strategy for enhancing cardioprotection.
Abstract

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...